DOCSLIB.ORG

Potency List 2021.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Potency List 2021.Xlsx Potency List Published 05.27.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes 2-Methoxyestradiol 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard 4-Aminophenol 3 $160 1 $240 0 $320 4-Aminopyridine 3 $160 1 $240 0 $320 5-Aminosalicylic Acid 3 $160 1 $240 0 $320 5-Fluorouracil 3 $260 1 $390 0 $520 5- Hydroxytryptophan 3 $160 1 $240 0 $320 5-Methyltetrahydrofolate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard 7-Keto DHEA 3 $160 1 $240 0 $320 7-Hydroxymitragynine 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard 13C - Urea 3 $710 1 $1,065 0 $1,420 Client to provide starting material or pay for standard 6,6 D2-Glucose 3 $210 1 $315 0 $420 Acebutolol 3 $160 1 $240 0 $320 Acepromazine 3 $160 1 $240 0 $320 Acepromazine Maleate 3 $160 1 $240 0 $320 Acetaminophen 3 $160 1 $240 0 $320 Acetate 3 $160 1 $240 0 $320 Acetazolamide 3 $160 1 $240 0 $320 Acetic Acid 3 $160 1 $240 0 $320 Acetohydroxamic Acid 3 $210 1 $315 0 $420 Acetyl Glucosamine 3 $160 1 $240 0 $320 Acetyl Hexapeptide 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Acetylcholine Chloride 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Acetylcysteine 3 $160 1 $240 0 $320 Drug list may not include consumables such as columns, standards, and special handling requests. Client will be contacted prior to initial testing for approval of additional expenses. Call ARL if you have a drug not on ARL's Drug List. (800) 393-1595 Potency List Published 05.27.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes Acetyl-D-Glucosamine 3 $160 1 $240 0 $320 Acetyl-L-Carnitine 3 $160 1 $240 0 $320 Acetyl-L-Cysteine 3 $160 1 $240 0 $320 Acetylsalicylic Acid 3 $160 1 $240 0 $320 Acid Alcohol 10 $360 7 $540 4 $720 Acitretin 3 $160 1 $240 0 $320 Actinomycin D 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Acyclovir 3 $160 1 $240 0 $320 Adapalene 3 $260 1 $390 0 $520 Adenine HCl 3 $160 1 $240 0 $320 Adenosine 3 $160 1 $240 0 $320 Client must indicate if the sample is Adenosine free base or phosphate Adenosine Monophosphate 3 $160 1 $240 0 $320 Adenosine Phosphate 3 $160 1 $240 0 $320 Adenosine Triphosphate 3 $160 1 $240 0 $320 Adenosyl 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Adenosylcobalamin 3 $160 1 $240 0 $320 Adequan 3 $210 1 $315 0 $420 Alanine 5 $360 3 $540 2 $720 Alanine-Glutamine 3 $360 1 $540 0 $720 Albendazole 3 $160 1 $240 0 $320 Albuterol 3 $210 1 $315 0 $420 Albuterol Sulfate 3 $210 1 $315 0 $420 Alcohol 10 $360 7 $540 4 $720 Drug list may not include consumables such as columns, standards, and special handling requests. Client will be contacted prior to initial testing for approval of additional expenses. Call ARL if you have a drug not on ARL's Drug List. (800) 393-1595 Potency List Published 05.27.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes Will be tested as 2 separate drugs: Hydrochlorothiazide and Spironolactone (charges will apply for Aldactazide See Note See Note See Note See Note See Note See Note both) Aldosterone 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Alendronate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Alendronate Sodium Trihydrate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Alfentanil HCL 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Allantoin 3 $160 1 $240 0 $320 Allithiamine Cream 3 $160 1 $240 0 $320 Allopurinol 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Alpha-glycerylphosphorylcholine (Alpha-GPC) 3 $510 1 $765 0 $1,020 Client to provide starting material or pay for standard Alpha-Ketoisocaproic Acid 3 $160 1 $240 0 $320 Alpha Lipoic Acid 3 $160 1 $240 0 $320 Alpha Thymosin Acetate 3 $210 1 $315 0 $420 Alprazolam 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Alprostadil 3 $160 1 $240 0 $320 Cannot test concentrations less than 5 mcg/mL. Cannot Super Rush if mixed with other actives. Altrenogest 3 $160 1 $240 0 $320 Alum 3 $160 1 $240 0 $320 Client must indicate the specific type of alum (e.g. potassium alum, ammonium alum, etc.) Aluminium Chlorohydrate 3 $160 1 $240 0 $320 Aluminum 10 $160 7 $240 4 $320 Cannot test less than 0.5 ug/mL Amantadine HCl 10 $360 7 $540 4 $720 Ambroxol HCl 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Amifostine 3 $260 1 $390 0 $520 Drug list may not include consumables such as columns, standards, and special handling requests. Client will be contacted prior to initial testing for approval of additional expenses. Call ARL if you have a drug not on ARL's Drug List. (800) 393-1595 Potency List Published 05.27.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes Amikacin 3 $260 1 $390 0 $520 Amikacin Sulfate 3 $260 1 $390 0 $520 Amiloride HCl Dihydrate 3 $160 1 $240 0 $320 Aminobenzoate Potassium 3 $160 1 $240 0 $320 Aminobutyric Acid 3 $160 1 $240 0 $320 Aminocaproic Acid 3 $160 1 $240 0 $320 Aminohippuric Acid Sodium 3 $210 1 $315 0 $420 Aminolevulinic Acid 3 $160 1 $240 0 $320 Aminolevulinic Acid HCl 3 $160 1 $240 0 $320 Aminopentamide Sulfate 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Aminophylline 3 $160 1 $240 0 $320 Aminophylline Injection (equlivalent Thoephylline) 3 $160 1 $240 0 $320 Aminopyridine 3 $160 1 $240 0 $320 Amiodarone 3 $160 1 $240 0 $320 Amiodarone HCl 3 $160 1 $240 0 $320 Amitraz 3 $160 1 $240 0 $320 Client to provide starting material or pay for standard Amitriptyline 3 $160 1 $240 0 $320 Amitriptyline HCl 3 $160 1 $240 0 $320 Amlexanox 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Amlodipine 3 $160 1 $240 0 $320 Amlodipine Besylate 3 $160 1 $240 0 $320 Ammonium Aluminum Sulfate 3 $160 1 $240 0 $320 Ammonium Chloride 10 $360 7 $540 4 $720 Drug list may not include consumables such as columns, standards, and special handling requests. Client will be contacted prior to initial testing for approval of additional expenses. Call ARL if you have a drug not on ARL's Drug List. (800) 393-1595 Potency List Published 05.27.2021 # of Actives Turnaround Time (in business days) Tested Standard Rush* Super Rush 1-3 See Table Below See Table Below See Table Below Potency 4-8 1 day/active 0.5 day/active Call for TAT 9+ Call for TAT Call for TAT Call for TAT 1-3 Add 1 Day to Table Below Add 1 Day to Table Below Add 1 Day to Table Below Potency (Cream/Gel/Ointment) 4-8 10 5 Call for TAT 9+ Call for TAT Call for TAT Call for TAT Standard Rush Super Rush Active Days Price Days Price Days Price Notes Ammonium Glycyrrhizinate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Ammonium Molybdate 3 $160 1 $240 0 $320 Ammonium Sulfate 3 $160 1 $240 0 $320 Ammonium Tetrathiomolybdate 10 $160 7 $240 4 $320 Amodiaquine HCl 3 $160 1 $240 0 $320 Amoxicillin 3 $160 1 $240 0 $320 Amoxicillin Trihydrate 3 $160 1 $240 0 $320 Amphetamine 10 $260 7 $390 4 $520 Amphetamine Sulfate 10 $260 7 $390 4 $520 Ampho-B 3 $210 1 $315 0 $420 Amphotericin B 3 $210 1 $315 0 $420 Ampicillin 3 $160 1 $240 0 $320 Anastrozole 3 $160 1 $240 0 $320 Androstenedione 3 $160 1 $240 0 $320 Angiotensin 1-7 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Anidulafungin 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard AOD-9604 Acetate 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Apomorphine 3 $160 1 $240 0 $320 Apomorphine HCl 3 $160 1 $240 0 $320 Apremilast 3 $210 1 $315 0 $420 Client to provide starting material or pay for standard Aprepitant 3 $160 1 $240 0 $320 Argatroban 3 $160 1 $240 0 $320 Arginine 3 $160 1 $240 0 $320 Drug list may not include consumables such as columns, standards, and special handling requests.
Load more

Recommended publications
  • Analysis of Drugs Manual September 2019
    Drug Enforcement Administration Office of Forensic Sciences Analysis of Drugs Manual September 2019 Date Posted: 10/23/2019 Analysis of Drugs Manual Revision: 4 Issue Date: September 5, 2019 Effective Date: September 9, 2019 Approved By: Nelson A. Santos Table of Contents CHAPTER 1 – QUALITY ASSURANCE ......................................................................... 3 CHAPTER 2 – EVIDENCE ANALYSIS ......................................................................... 93 CHAPTER 3 – FIELD ASSISTANCE .......................................................................... 165 CHAPTER 4 – FINGERPRINT AND SPECIAL PROGRAMS ..................................... 179 Appendix 1A – Definitions ........................................................................................... 202 Appendix 1B – Acronyms and Abbreviations .............................................................. 211 Appendix 1C – Instrument Maintenance Schedule ..................................................... 218 Appendix 1D – Color Test Reagent Preparation and Procedures ............................... 224 Appendix 1E – Crystal and Precipitate Test Reagent Preparation and Procedures .... 241 Appendix 1F – Thin Layer Chromatography................................................................ 250 Appendix 1G – Qualitative Method Modifications ........................................................ 254 Appendix 1H – Analytical Supplies and Services ........................................................ 256 Appendix 2A – Random Sampling Procedures
    [Show full text]
  • Erteberel (LY500307) Product Data Sheet
    Product Name: Erteberel (LY500307) Revision Date: 01/10/2021 Product Data Sheet Erteberel (LY500307) Cat. No.: B1518 CAS No.: 533884-09-2 Formula: C18H18O3 M.Wt: 282.33 Synonyms: Target: Endocrinology and Hormones Pathway: Estrogen/progestogen Receptor Storage: Store at -20°C Solvent & Solubility insoluble in H2O; ≥14.1 mg/mL in DMSO; ≥48.3 mg/mL in EtOH Mass Solvent 1mg 5mg 10mg Preparing Concentration In Vitro Stock Solutions 1 mM 3.5420 mL 17.7098 mL 35.4195 mL 5 mM 0.7084 mL 3.5420 mL 7.0839 mL 10 mM 0.3542 mL 1.7710 mL 3.5420 mL Please refer to the solubility information to select the appropriate solvent. Biological Activity Shortsummary ERβ agonist, potent and selective IC₅₀ & Target Cell Viability Assay Cell Line: Human prostate cancer cell line (PC-3 cells) Preparation method： The solubility of this compound in DMSO is >10 mM. General tips for obtaining In Vitro a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months. Reacting conditions: N/A 1 | www.apexbt.com Applications: Erteberel showed potent and selective binding affinity for ERβ with EC50 value of 0.66 nM [1]. Animal experiment Animal models: Male and female rat fertility and rat and rabbit embryo-fetal development model Dosage form: 0.03 to 10 mg/kg/day for rats, or 1 to 25 mg/kg/day for rabbits, oral gavage, for 2 or 10 weeks Applications: There were no-observed adverse effect levels following LY500307 In Vivo administration of 1 mg/kg/day for male rat fertility, 0.3 mg/kg/day for female rat fertility and embryo-fetal development, and 25 mg/kg/day for rabbit embryo-fetal development [2].
    [Show full text]
  • Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
    cells Article Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma Tamara T. Lah 1,2,3,*, Metka Novak 1, Milagros A. Pena Almidon 4, Oliviero Marinelli 4 , Barbara Žvar Baškoviˇc 1, Bernarda Majc 1,3, Mateja Mlinar 1, Roman Bošnjak 5, Barbara Breznik 1 , Roby Zomer 6 and Massimo Nabissi 4 1 Department of Genetic Toxicology and Cancer Biology, National Institute of Biology, 1000 Ljubljana, Slovenia; [email protected] (M.N.); [email protected] (B.Ž.B.); [email protected] (B.M.); [email protected] (M.M.); [email protected] (B.B.) 2 Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia 3 Jožef Stefan International Postgraduate School, 1000 Ljubljana, Slovenia 4 School of Pharmacy, Experimental Medicine Section, University of Camerino, 62032 Camerino, Italy; [email protected] (M.A.P.A.); [email protected] (O.M.); [email protected] (M.N.) 5 Department of Neurosurgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia; [email protected] 6 MGC Pharmaceuticals d.o.o., 1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +386-41-651-629 Simple Summary: Among primary brain tumours, glioblastoma is the most aggressive. As early relapses are unavoidable despite standard-of-care treatment, the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone or in combination have been suggested as a combined treatment strategy for glioblastomas. However, the known psychoactive effects of THC hamper its medical applications in these patients with potential cognitive impairment due to the progression of the Citation: Lah, T.T.; Novak, M.; Pena Almidon, M.A.; Marinelli, O.; disease.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • A Dissertation Entitled Uncovering Cannabinoid Signaling in C. Elegans
    A Dissertation Entitled Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medicinal Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology ________________________________________ Dr. Richard Komuniecki, Committee Chair _______________________________________ Dr. Bruce Bamber, Committee Member ________________________________________ Dr. Patricia Komuniecki, Committee Member ________________________________________ Dr. Robert Steven, Committee Member ________________________________________ Dr. Ajith Karunarathne, Committee Member ________________________________________ Dr. Jianyang Du, Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo August 2018 Copyright 2018, Mitchell Duane Oakes This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Uncovering Cannabinoid Signaling in C. elegans: A New Platform to Study the Effects of Medical Cannabis By Mitchell Duane Oakes Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biology The University of Toledo August 2018 Cannabis or marijuana, a popular recreational drug, alters sensory perception and exerts a range of medicinal benefits. The present study demonstrates that C. elegans exposed to
    [Show full text]
  • Microgram Journal, Vol 2, Number 1
    Washington, D. C. Office of Science and Education Vol.II,No.1 Division of Laboratory Operations January 1969 INDEXISSUE CORRECTION 11 "Structure Elucidation of 'LBJ' , by Sander W. Bellman, John W. Turczan, James Heagy and Ted M. Hopes, Micro­ Gram .!., 3, 6-13 (Dec. 1968) Page 7, third and fourth sentences under Discussion: Change to read: "The melting point of the acid moiety found in step (g) was 148-150°c., compared to the litera­ ture, v~lue of 151°c for the melting point of benzilic acid (2); thus the benzilic acid melting point gives support to the proposed structure for 'LBJ'. Spectral evidence also supports the proposed structure". MICRO-GRAMREVISION Please re-number the pages of your copies of Micro-Gram, Volume I. Re-number pages bearing printing only. Vol­ ume I will then be numbered from page 1, the front page of issue No. 1, through page 189 the last page of issue No. 12. To help with this task, pages contained within each issue are as follows: Issue Number Page Through 1 1 8 2 9 29 3 30 32 4 33 66 5 67 79 6 80 97 7 98 120 8 121 128 9 129 136 10 137 157 11 158 170 12 171 189 CAUTION: Use of this publication should be restricted to forensic analysts or others having a legitimate need for this material. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -2- CANNABIS ,·,-...__/' Attached is a copy of 11A Short Rapid Method for the Identification of Cannabis." The method was developed by Mro H.D.
    [Show full text]
  • Tuning Drug Release from Polyoxazoline-Drug Conjugates T ⁎ J
    European Polymer Journal 120 (2019) 109241 Contents lists available at ScienceDirect European Polymer Journal journal homepage: www.elsevier.com/locate/europolj Tuning drug release from polyoxazoline-drug conjugates T ⁎ J. Milton Harrisa, ,1, Michael D. Bentleya, Randall W. Moreaditha, Tacey X. Viegasa,1, Zhihao Fanga, Kunsang Yoona, Rebecca Weimera, Bekir Dizmanb, Lars Nordstiernac a Serina Therapeutics, Inc., 601 Genome Way, Suite 2001, Huntsville, AL 35806, USA2 b Sabanci University, Faculty of Engineering and Natural Sciences, Tuzla, 34956 İstanbul, Turkey2 c Department of Chemistry and Chemical Engineering, Chalmers University of Technology, SE-412 96 Göteborg, Sweden ARTICLE INFO ABSTRACT Keywords: Poly(2-oxazoline)-drug conjugates with drugs attached via releasable linkages are being developed for drug Poly(2-oxazoline) or POZ delivery. Such conjugates with pendent ester linkages that covalently bind drugs to the polymer backbone ex- Poly(2-ethyl-2-oxazoline) or PEOZ hibit significantly slower hydrolytic release rates in plasma than the corresponding PEG- and dextran-drug Pendent drugs conjugates. The slow drug release rates in-vitro of these POZ-drug conjugates contribute to extended in-vivo Degradable ester linkages pharmacokinetic profiles. In some instances, the release kinetics may be relatively sustained and ideal foronce-a- Pharmacokinetics week subcutaneous injection, whereas the native drug by itself may only have an in-vivo half-life of a few hours. Drug delivery Phenolic drugs The origin of this unusual kinetic and pharmacokinetic behavior is proposed here to involve folding of the POZ conjugate such that the relatively hydrophobic drug forms a central core, and the relatively hydrophilic polymer wraps around the core and slows enzymatic attack on the drug-polymer chemical linkage.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 24, No. 4, 2010 World Health Organization WHO Drug Information Contents WHO Prequalification Sitaxentan: worldwide withdrawal 307 Programmes Sibutramine: suspension of sales 307 Sibutramine-containing medicines: WHO Prequalification of Medicines withdrawal 308 Programme: survey of service Testosterone transdermal patch: quality provided to manufacturers 293 withdrawal of extension of WHO initiates pilot prequalification of indication application 308 active pharmaceutical ingredients 297 Aliskiren/valsartan: withdrawal of New on-line database for WHO marketing authorization application 308 prequalified vaccines 298 Mometasone furoate/formoterol fumarate: withdrawal of marketing Safety and Efficacy Issues authorization application 309 EMA and US FDA extend confidentiality H1N1 influenza vaccine: narcolepsy 299 arrangements indefinitely 309 Statins: interstitial lung disease 299 Tocilizumab: risk of fatal anaphylaxis 300 Recent Publications, Pioglitazone: potential bladder cancer 301 Information and Events Angiotensin receptor blockers and US Government to share patents with cancer: safety review 301 Medicines Patent Pool 310 GnRH agonists, diabetes and cardio- Clinical trials and global medicines vascular disease 301 development 310 Gadolinium-based contrast agents: Evaluation of future nanomedicines 311 kidney dysfunction 302 Reporting on opioid inaccessibility 311 Lamotrigine: aseptic meningitis Tinzaparin sodium: renal Impairment in elderly 303 Consultation Documents Tamoxifen: drug interactions involving The
    [Show full text]
  • TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub
    US 20200187851A1TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0187851 A1 Offenbacher et al. (43 ) Pub . Date : Jun . 18 , 2020 ( 54 ) PERIODONTAL DISEASE STRATIFICATION (52 ) U.S. CI. AND USES THEREOF CPC A61B 5/4552 (2013.01 ) ; G16H 20/10 ( 71) Applicant: The University of North Carolina at ( 2018.01) ; A61B 5/7275 ( 2013.01) ; A61B Chapel Hill , Chapel Hill , NC (US ) 5/7264 ( 2013.01 ) ( 72 ) Inventors: Steven Offenbacher, Chapel Hill , NC (US ) ; Thiago Morelli , Durham , NC ( 57 ) ABSTRACT (US ) ; Kevin Lee Moss, Graham , NC ( US ) ; James Douglas Beck , Chapel Described herein are methods of classifying periodontal Hill , NC (US ) patients and individual teeth . For example , disclosed is a method of diagnosing periodontal disease and / or risk of ( 21) Appl. No .: 16 /713,874 tooth loss in a subject that involves classifying teeth into one of 7 classes of periodontal disease. The method can include ( 22 ) Filed : Dec. 13 , 2019 the step of performing a dental examination on a patient and Related U.S. Application Data determining a periodontal profile class ( PPC ) . The method can further include the step of determining for each tooth a ( 60 ) Provisional application No.62 / 780,675 , filed on Dec. Tooth Profile Class ( TPC ) . The PPC and TPC can be used 17 , 2018 together to generate a composite risk score for an individual, which is referred to herein as the Index of Periodontal Risk Publication Classification ( IPR ) . In some embodiments , each stage of the disclosed (51 ) Int. Cl. PPC system is characterized by unique single nucleotide A61B 5/00 ( 2006.01 ) polymorphisms (SNPs ) associated with unique pathways , G16H 20/10 ( 2006.01 ) identifying unique druggable targets for each stage .
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • Annual Report © 2018 Ciberned
    2018 ANNUAL REPORT © 2018 CIBERNED Coordination and management of content: Miguel Medina Padilla José de Arriba-Enríquez Aina Frontera Sánchez Almudena Flores Junquera Soledad Valero Rodríguez Design and editorial coordination: OnAccent.com CIBERNED 2018 ANNUAL REPORT INDEX 005 | Letter from the Scientific Director 006 | Introduction 009 | Aims 010 | Directory of research groups and associated institutions 012 | Geographic distribution of CIBERNED research groups 013 | Organizational structure 014 | Organization chart 015 | External scientific advisory committee 016 | Consortium members 017 | Research programmes 019 | Program 1: Alzheimer’s disease and other degenerative dementias 107 | Program 2: Parkinson’s and Huntington’s disease and other degenerative movement disorders 219 | Program 3: Amyotrophic Lateral Sclerosis and other neuromuscular disorders 257 | Cooperative research 279 | International relations 291 | Scientific productivity and other activities 307 | Finantial report 333 | Index of investigators 3 4 CIBERNED 2018 ANNUAL REPORT Jesús Ávila de Grado SCIENTIFIC DIRECTOR LETTER FROM THE SCIENTIFIC DIRECTOR As in previous years, I would like to begin by highlighting the excellent work of the re- search groups that make up CIBERNED and that has allowed us, once again, to be at the forefront of the Centers in biomedical research regarding the quality of publications in high- impact index scientific journals. In order to carry out this work, we have counted on the help and collaboration of the Management Office and the Steering Committee of the Center, as well as its support staff, and the help of the Carlos III Institute of Health and the Associated Institutions. A very important novelty has been the incorporation of six new research groups to CIBERNED, led by Drs.
    [Show full text]
  • The Use of Cannabinoids in Animals and Therapeutic Implications for Veterinary Medicine: a Review
    Veterinarni Medicina, 61, 2016 (3): 111–122 Review Article doi: 10.17221/8762-VETMED The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review L. Landa1, A. Sulcova2, P. Gbelec3 1Faculty of Medicine, Masaryk University, Brno, Czech Republic 2Central European Institute of Technology, Masaryk University, Brno, Czech Republic 3Veterinary Hospital and Ambulance AA Vet, Prague, Czech Republic ABSTRACT: Cannabinoids/medical marijuana and their possible therapeutic use have received increased atten- tion in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veteri- nary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific lit- erature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary
    [Show full text]